Equities analysts predict that Qiagen NV (NYSE:QGEN) will announce earnings per share of $0.34 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Qiagen’s earnings, with the highest EPS estimate coming in at $0.34 and the lowest estimate coming in at $0.33. Qiagen posted earnings per share of $0.33 in the same quarter last year, which indicates a positive year-over-year growth rate of 3%. The business is expected to announce its next earnings results after the market closes on Tuesday, July 30th.
According to Zacks, analysts expect that Qiagen will report full year earnings of $1.44 per share for the current fiscal year, with EPS estimates ranging from $1.42 to $1.45. For the next financial year, analysts anticipate that the company will post earnings of $1.60 per share, with EPS estimates ranging from $1.54 to $1.63. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Qiagen.
Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, May 6th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. The company had revenue of $348.70 million for the quarter, compared to the consensus estimate of $351.68 million. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period last year, the business posted $0.26 EPS.
QGEN has been the topic of a number of research reports. Deutsche Bank downgraded Ontex Group from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Barclays raised their price objective on from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the stock an “equal weight” rating in a report on Friday, June 21st. Zacks Investment Research downgraded Great Portland Estates from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Wolfe Research initiated coverage on Waters in a report on Thursday, May 30th. They issued an “underperform” rating on the stock. Finally, Exane BNP Paribas upgraded Qiagen from a “neutral” rating to an “outperform” rating in a report on Friday. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Qiagen presently has an average rating of “Buy” and an average target price of $42.00.
Shares of Qiagen stock traded up $0.27 during trading hours on Wednesday, reaching $39.96. The stock had a trading volume of 32,291 shares, compared to its average volume of 655,976. The business’s 50 day simple moving average is $39.53. The firm has a market capitalization of $8.95 billion, a price-to-earnings ratio of 29.80, a price-to-earnings-growth ratio of 2.43 and a beta of 0.84. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.69 and a quick ratio of 1.52. Qiagen has a 1 year low of $32.33 and a 1 year high of $41.55.
Hedge funds have recently bought and sold shares of the company. LPL Financial LLC increased its stake in Qiagen by 11.4% during the 4th quarter. LPL Financial LLC now owns 10,932 shares of the company’s stock valued at $377,000 after purchasing an additional 1,123 shares in the last quarter. BlackRock Inc. increased its stake in Qiagen by 5.4% during the 4th quarter. BlackRock Inc. now owns 6,607,877 shares of the company’s stock valued at $227,642,000 after purchasing an additional 336,763 shares in the last quarter. Martingale Asset Management L P increased its stake in Qiagen by 33.8% during the 4th quarter. Martingale Asset Management L P now owns 23,061 shares of the company’s stock valued at $796,000 after purchasing an additional 5,826 shares in the last quarter. Northern Trust Corp increased its stake in Qiagen by 0.4% during the 4th quarter. Northern Trust Corp now owns 739,567 shares of the company’s stock valued at $25,477,000 after purchasing an additional 2,630 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Qiagen by 44.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 41,397 shares of the company’s stock valued at $1,426,000 after purchasing an additional 12,792 shares in the last quarter. Institutional investors and hedge funds own 63.20% of the company’s stock.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
Get a free copy of the Zacks research report on Qiagen (QGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.